Like Sun Pharma, Granules India, Suven Life: Devang Mehta

Devang Mehta of Anand Rathi Financial Services told CNBC-TV18, "We continue to like Sun Pharmaceutical Industries. We feel that one or two quarters still could be a little bit of overhang of Ranbaxy merger but we continue to like it as well Lupin post the big correction that we have seen in the past few months.""In the midcaps we continue to like stocks like Granules India and Suven Life Sciences, both trading 15 price to earnings (PE) one year forward. So, this has lot of trigger going forward," he said.